Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveRole of Akt signaling in resistance to DNA-targeted therapyFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerPhase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.Development of a fluorescence resonance energy transfer-based intracellular assay to identify novel enterovirus 71 antivirals.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.The Promises of Quantitative Proteomics in Precision MedicinePharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Liposomal chemotherapeutics.Novel developments in the use of antimetabolites.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma.miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxiaTGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma.5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.
P2860
Q26752368-A335026D-DF7A-4371-B8F4-81BBE9ADBB86Q28066950-5CD86284-D9E6-4429-97C1-71A4954A58E0Q28075540-9E084822-A463-4989-8138-1AD0DC754BD2Q33416342-346EA4CA-6E96-403A-A706-38E21E2674B0Q34906454-472087AA-91A2-49D9-A73E-81BC4C1EA7A4Q35039916-22FA08C9-3FFC-42B9-8A22-EE3BA53CC4C5Q36200660-A903E852-5F34-4753-A123-DB214AA14B64Q37569554-6CC8AFCB-077F-4286-A283-39F25FA1CAC7Q37647264-4BFB047A-CA89-4741-8489-F12F1CECB60DQ38030053-595859A2-17C3-4B3F-8A10-33E823B025BFQ38167883-D0115268-7368-4D80-B887-066F51982BE3Q38221152-E89E9CD4-9F86-4DD6-B716-45DB5E637374Q38673319-9860463B-AE22-4EDD-9C75-7DD68714411DQ38728079-207225A3-B171-4E8A-85F2-6EF782BE2142Q38760434-89318410-E886-4F99-9D44-670D7737C191Q38957259-CA457857-62CB-4779-A5F6-A5DB77C45BCDQ38983476-8864674C-112E-4E4C-90CA-CA5925C4F05EQ39017796-F3294103-F364-4513-BBD8-9F43E35ACE67Q39068039-BDE39E87-AAB7-4054-9DAD-65532E66FDE2Q40590883-25AC5009-045D-4238-AA69-7B8797752665Q47830761-F4581410-57BA-4399-B92C-8F457BF7EF27Q49387560-5F795FC0-627E-4874-9A62-A30D2A6989EDQ50468405-CC49BE9C-6F1B-46F1-A406-C6C89DB51722Q50895128-94339501-FF86-4A5A-AC86-53A3371B094AQ52584335-23C7CE3B-E205-46B0-B28E-2756CED845F2
P2860
Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@en
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@nl
type
label
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@en
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@nl
prefLabel
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@en
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@nl
P2093
P1476
Molecular targets of gemcitabi ...... l drugs and drug combinations.
@en
P2093
Elisa Giovannetti
Godefridus J Peters
Maha Elnaggar
P304
P356
10.2174/138161212800626175
P577
2012-01-01T00:00:00Z